Insider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Sells $317,250.00 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $21.18 on Friday. The company has a market cap of $5.01 billion, a PE ratio of 75.64 and a beta of 0.64. The firm’s 50 day moving average price is $18.86 and its 200-day moving average price is $14.83. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter last year, the firm earned $0.01 EPS. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

A number of large investors have recently added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky purchased a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $1,047,000. Neo Ivy Capital Management acquired a new position in shares of ADMA Biologics during the third quarter worth $972,000. Geode Capital Management LLC increased its position in shares of ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Barclays PLC lifted its holdings in shares of ADMA Biologics by 192.2% during the 3rd quarter. Barclays PLC now owns 528,629 shares of the biotechnology company’s stock valued at $10,567,000 after purchasing an additional 347,692 shares during the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of ADMA Biologics in the 3rd quarter worth $5,757,000. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ADMA shares. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.